Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke

Diabetes and Vascular Disease Research

Volumn 12, Issue 6, 2015, Pages 463-466

  Tziomalos, Konstantinos ^a   Bouziana, Stella D ^a   Spanou, Marianna ^a   Kostaki, Stavroula ^a   Papadopoulou, Maria ^a   Giampatzis, Vasilios ^a   Dourliou, Vasiliki ^a   Kostourou, Danai Thomais ^a   Savopoulos, Christos ^a   Hatzitolios, Apostolos I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

dipeptidyl peptidase 4 inhibitors; insulin; Ischaemic stroke; metformin; sulfonylureas; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; PROSPECTIVE STUDY; RANKIN SCALE; SCORING SYSTEM; TREATMENT OUTCOME; COMPLICATION; HOSPITAL MORTALITY; MIDDLE AGED; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

EID: 84945258297     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115597867     Document Type: Article

References (12)

1. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
2. Hatzitolios AI, Didangelos TP, Zantidis AT, et al. Diabetes mellitus and cerebrovascular disease: which are the actual data? J Diabetes Complications 2009; 23: 283-296.
3. Darsalia V, Ortsäter H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes 2013; 62: 1289-1296.
4. Li J, Benashski SE, Venna VR, et al. Effects of metformin in experimental stroke. Stroke 2010; 41: 2645-2652.
5. Magkou D, Tziomalos K,. Antidiabetic treatment, stroke severity and outcome. World J Diabetes 2014; 5: 84-88.
6. Weih M, Amberger N, Wegener S, et al. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 2001; 32: 2029-2032.
7. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38: 2526-2530.
8. Favilla CG, Mullen MT, Ali M, et al.; Virtual International Stroke Trials Archive (VISTA) Collaboration. Sulfonylurea use before stroke does not influence outcome. Stroke 2011; 42: 710-715.
9. Horsdal HT, Mehnert F, Rungby J, et al. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. J Stroke Cerebrovasc Dis 2012; 21: 717-725.
10. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
11. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
12. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.